Portfolio Analysis in Madrid.

A patent portfolio analysis Madrid owners can act on has to start from one fact that sets Spain apart from most of Europe: Spain never joined the unitary patent or the Unified Patent Court, so a Spanish estate is still enforced country by country, before Spanish judges, under Spanish law. Madrid is the capital of that system — it is the seat of the Spanish Patent and Trademark Office (OEPM) on the Paseo de la Castellana, and the corporate home of Telefónica, Repsol and the banking and energy groups whose patent budgets run into the millions. The questions asked of an estate here are therefore national ones: how does a European patent take effect in Spain, what does Spanish validation cost, and where would the portfolio actually be litigated?

The work is landscape, gap, strength and valuation analysis — not litigation. It is the freedom-to-operate map behind a new product launch in the Spanish market, the read on pharma supplementary-protection-certificate exposure a life-science estate needs, the diligence behind a Madrid acquisition, and the pruning decision that stops a large estate overspending on annuities and translations. PerspireIP builds those studies for the pharmaceutical, telecoms, energy, banking and deep-tech portfolio owners across Madrid and the wider Community of Madrid.

Why patent portfolio analysis Madrid owners frame around national-only enforcement

Here is the fact that reshapes every patent portfolio analysis Madrid companies commission. Spain is a member of the European Patent Convention, but it deliberately stayed out of the unitary patent and the Unified Patent Court. Spain challenged the package before the Court of Justice of the European Union and lost in 2015 (Cases C-146/13 and C-147/13), and it has since confirmed it will not join. The practical consequence is decisive: a European patent cannot have unitary effect in Spain, and no UPC ruling reaches Spanish territory. A patent takes effect here only as a national Spanish right, and it can be enforced or revoked only before the Spanish courts.

That changes the deliverable compared with a UPC-member city such as Munich, Paris or Milan. In those jurisdictions a single central action can injunct or revoke a patent across a dozen states at once, so a review has to grade opt-out posture and pan-European exposure. In Madrid the analysis is national: it reads how each family stands as a Spanish right, whether the Spanish leg of a European filing was validated correctly, and how it would fare before a Spanish commercial court. For a portfolio owner that means Spain is a separate line item in the enforcement and budget picture, never folded into a unitary bundle.

• National validity and coverage — how each family stands as a Spanish right, independent of any UPC or unitary title
• Freedom to operate in Spain — clearance before a product launch or market entry in the Spanish market
• Deal and supplier diligence — validity, ownership chain and product coverage of a Madrid target’s patents before a transaction
• Board and budget reviews — a periodic strength, gap and renewal-cost picture for the general counsel and the CFO

The OEPM in Madrid: national filings, the PCT search route and SPCs

Madrid is not just where Spanish portfolios are managed — it is where the national office sits. The Spanish Patent and Trademark Office (OEPM), an agency of the Ministry of Industry, is headquartered on the Paseo de la Castellana in Madrid, and it grants national Spanish patents after a substantive novelty and inventive-step examination. Most large Spanish estates blend three routes: direct national OEPM filings, European patents validated into Spain, and international PCT applications. A portfolio analysis has to read which route each family took, because the route shapes prosecution history, cost and how defensible a family looks to a later buyer, licensee or opponent.

There is a route many Spanish applicants under-use. The OEPM is not only a national office but a Patent Cooperation Treaty Receiving Office and one of the world’s International Searching and Preliminary Examining Authorities, and the PCT has been in force in Spain since 16 November 1989. A Spanish applicant can have the OEPM run the international search and preliminary examination on a PCT application in Spanish. The quality and timing of that first search shapes how a family matures, so the analysis reads which international applications went through the OEPM, the EPO or another authority.

The OEPM also administers supplementary protection certificates (SPCs). Under EC Regulation 469/2009 an SPC can extend Spanish protection for a patented medicine or plant-protection product with a valid Spanish marketing authorisation for up to five years beyond the 20-year patent term. For a Madrid pharma estate the SPC layer is often where the real commercial life of a molecule sits, so any credible portfolio analysis Madrid life-science owners rely on must map SPC status, term and eligibility family by family, not just the base patents.

Spanish-translation validation and what it costs a Madrid estate

Spain is one of the more expensive places in Europe to keep a European patent alive, and a patent portfolio analysis Madrid owners trust has to price that in. Spain is not a party to the London Agreement, so it uses the option in Article 65 EPC to demand a translation of the granted patent into Spanish. In practice the proprietor must file a full Spanish translation of the entire specification — description and claims — at the OEPM within three months of the European Patent Office publishing the mention of grant. Miss that window and the European patent simply has no effect in Spain: there is no national right left to enforce.

That single rule drives real portfolio decisions. Full-specification translation is a meaningful per-family cost, especially for the long, complex specifications common in pharma, chemistry and telecoms, so validating into Spain is a deliberate choice rather than a default. A review reads whether each European family was actually validated in Spain, whether the translation deadline was met, and whether Spain still earns its place in the country list for that technology and market. For an estate spread across many EPC states, deciding where Spanish validation is worth the translation and annuity spend is one of the highest-leverage calls the analysis surfaces.

Renewals compound the picture. National Spanish patents and validated European patents both carry annuities paid to the OEPM that escalate every year, and a lapsed translation or a missed annuity kills the Spanish leg outright. A pruning analysis scores every family before its next Spanish renewal against three tests — does it still cover a product or roadmap item in the Spanish market, does it block a competitor here, and would a buyer or licensee pay for the Spanish right. For a large estate that exercise usually pays for the whole review while catching the opposite error: a strategic family drifting toward a lapse that costs far more than the fee saved.

Barcelona versus Madrid: where a Spanish patent is actually litigated

Madrid is the corporate and administrative capital, but it is not automatically the litigation capital for patents. Spain funnels patent cases into a small set of specialised commercial courts (juzgados de lo mercantil) with exclusive jurisdiction over patents, and these courts hear both infringement and validity in the same proceedings. Barcelona (commercial courts 1, 4 and 5), Madrid (commercial courts 6 through 11) and Valencia (Mercantil nº 2) were the original specialised venues; since 2019 the specialisation has extended to Granada, Las Palmas de Gran Canaria, A Coruña and Bilbao. Only these courts can decide a Spanish patent dispute.

The counter-intuitive point for a Madrid portfolio owner is that Barcelona, not Madrid, is the dominant patent forum. The Barcelona commercial courts and the specialist commercial section of the Barcelona provincial appellate court (Audiencia Provincial de Barcelona, Sección 15) are widely regarded as the most experienced patent judges in Spain, and a large share of Spanish patent infringement claims — particularly pharma cases — are filed there. Madrid’s commercial courts and its own specialist appellate section handle substantial patent work too, but the choice of venue is a strategic one that a portfolio analysis should flag before a dispute rather than during one.

For a Madrid-headquartered company that has two consequences. First, the estate has to be graded for how it would read before Spanish judges applying Spanish validity and claim-construction case law, which has developed independently of the UPC. Second, forum choice within Spain matters: an owner planning to assert a family should understand where the strongest, fastest and most predictable hearing lies, and a defendant facing a Spanish threat should know which court is likely to see the case. We map each key family to the venue and case law most relevant to it, so the litigation picture is part of the portfolio picture.

Grading Madrid’s pharma, telecoms, energy and banking estates

Madrid concentrates a particular mix of patent-owning industries, and each one hides its value in a different place. The city is the corporate home of Telefónica, headquartered at the Distrito Telefónica campus in Las Tablas, and of energy majors including Repsol; the operational campuses of Spain’s largest banks — Banco Santander at Boadilla del Monte and BBVA’s Ciudad BBVA — sit in the Community of Madrid, driving a growing fintech and payments patent base. A patent portfolio analysis Madrid counsel can act on has to read a telecoms, energy or banking estate on its own terms rather than by counting granted claims.

Life science is the pillar where the Spanish rules bite hardest. The Madrid region hosts pharmaceutical companies such as Laboratorios Rovi and PharmaMar (in Colmenar Viejo), plus a dense network of hospitals and research institutes. Pharma estates live and die on a handful of composition-of-matter, formulation and second-medical-use families, and their commercial tail is the SPC. Because Spain demands full Spanish validation and administers its own SPCs through the OEPM, the Spanish leg of a pharma portfolio needs individual attention: which molecules are validated here, which carry a Spanish SPC, and how exposed each is to generic entry before the Barcelona courts.

• Pharma and biotech — composition, formulation and second-medical-use families, graded with Spanish SPC status, term and generic-exposure risk
• Telecoms and connectivity — implementation and standards-related patents from the Telefónica ecosystem, read for essentiality and cross-licence leverage
• Energy and industrials — refining, renewables and grid inventions from the Repsol and utility estates, mapped to products and competitors
• Banking and fintech — payments, security and platform patents from the Santander and BBVA technology groups, an emerging Madrid filing base

Reading Madrid’s research spinouts, CSIC and deep-tech estates

Madrid’s patent base runs well beyond its listed corporates. The city is the headquarters of the Spanish National Research Council (CSIC), Europe’s largest public research organisation, and home to the National Cancer Research Centre (CNIO) and major universities including the Universidad Complutense, the Universidad Autónoma de Madrid and the Universidad Politécnica de Madrid. These institutions spin out companies whose entire valuation can rest on one foundational patent, and their estates need a different lens from a corporate portfolio: the question is not breadth but whether a single family genuinely covers the technology and would survive a validity attack.

For a spinout or an investor, the Spanish specifics still apply. A university family filed through the OEPM or the PCT has to be checked for clean ownership and inventorship, for whether the Spanish and foreign legs were validated and kept in force, and for freedom to operate against far larger assignees before it can carry a funding round or a licensing deal. We verify legal status and the ownership chain, confirm the claims actually read on the technology, map the competitive white space, and deliver a valuation view as data-room-ready exhibits, usually inside the raise or deal window.

Each of these estates hides its value differently, so a patent portfolio analysis Madrid founders and counsel trust reads each on its own terms. A CSIC or university spinout may carry one platform patent that underwrites its whole valuation; a deep-tech start-up a handful of mechanism families; a Madrid corporate a large mixed estate where most families are pruning candidates and a few are crown jewels. Counting patents tells you nothing useful about any of them — grading each against products, competitors, Spanish validity and SPC status tells you everything you need to raise, sell or defend a budget.

How PerspireIP builds a portfolio analysis you can act on

Every engagement follows the same disciplined path, scaled to whether you are clearing a launch in the Spanish market, defending a budget, prepping a data room or planning next year’s filings. We inventory the portfolio, verify legal status and ownership, map each asset to products and competitors, grade strength and Spanish validity, price the SPC and translation exposure, and value the estate for the decision that prompted the review.

• Full inventory with legal-status, term and renewal timeline for every asset across the OEPM, EPO and PCT routes
• Spanish validation and translation audit — which European families took effect in Spain and which lapsed at the three-month deadline
• SPC status, term and generic-exposure mapping for every pharma family with a Spanish marketing authorisation
• Product-to-patent coverage mapping and a claim-strength score read against Spanish validity and claim-construction case law
• Freedom-to-operate landscaping across the major assignees relevant to your Spanish market
• Renewal-fee pruning recommendations plus a valuation view for financing, M&A or licensing, delivered as data-room-ready exhibits

We work alongside your in-house IP team, corporate-development group or outside counsel as a specialist analysis partner, deliver to your product or budget calendar, and keep every engagement confidential. Whether you need a one-time diligence study before a Madrid acquisition, a Spanish freedom-to-operate read for a launch, or an annual portfolio health check for the board, we scale to fit. Send us the assignee name or a patent list and we will scope a patent portfolio analysis Madrid project within one business day.

IP Landscape & Resources in Madrid

Key intellectual-property authorities and venues relevant to Madrid:

• Spanish Patent and Trademark Office (OEPM) — the Madrid-seated national office that grants and examines Spanish patents, requires Spanish-language validation of European patents, administers SPCs and acts as a PCT International Searching and Preliminary Examining Authority
• European Patent Office (EPO) — grants the European patents that must be validated with a full Spanish translation to take effect in Spain, which sits outside the unitary patent system
• Consejo General del Poder Judicial (Spanish judiciary) — the body overseeing Spain's courts, including the specialised commercial courts (juzgados de lo mercantil) in Madrid, Barcelona and Valencia that hold exclusive patent jurisdiction
• Spanish National Research Council (CSIC) — Europe's largest public research organisation, headquartered in Madrid, whose spinouts and patent families anchor much of the region's deep-tech and life-science IP

Request a Patent Portfolio Analysis in Madrid

Explore related PerspireIP services: Patent Portfolio Analysis services · IP services in Spain · patent invalidation · prior art litigation search · patent infringement analysis · patent market research and landscaping.

Frequently Asked Questions